Cannabis Clinical Trials DEA Decriminalization 
SpeedWeed
SEPTEMBER 4, 2021
The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. Some states in the U.S.
Veriheal
JUNE 29, 2021
This Act permits individuals that have been diagnosed with life-threatening conditions or diseases that have exhausted all other approved treatment and therapeutic options that are also unable to participate in clinical trials the ability to access certain treatments that would otherwise be unapproved for access.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Canna Law Blog
NOVEMBER 6, 2021
The following year, President Richard Nixon declared drug abuse public enemy number one, and in 1973, he formed the Drug Enforcement Administration (DEA). But federal lawsuits on cannabis rescheduling provide guidance and suggest that FDA approval is not a requirement for meeting that criterion.
Veriheal
DECEMBER 21, 2022
This makes history by enacting the first piece of standalone federal cannabis reform legislation in U.S. It also creates a more efficient pathway for researchers who request larger quantities of cannabis. Manufacturers will also be allowed to import cannabis materials to facilitate research into the plant’s therapeutic potential.
NewsMunchies
NOVEMBER 12, 2021
As the cannabis industry continues to grow and evolve with legalization achieved in many parts of the world, we’re seeing an increase in activity related to another substance that will hopefully be removed from the list of controlled substances – psilocybin. Additional clinical trials underway in the U.S.
Cannabis Law Report
FEBRUARY 10, 2022
Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.
Cannabis Law Report
MAY 31, 2022
The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. Though, Oregon is actively in the process of establishing a model for psilocybin that would be like the state’s current medical cannabis system. Schedule I.
Expert insights. Personalized for you.
52 
Let's personalize your content